Co-reporter:Lei Zhang, Varun Dewan, and Hang Yin
Journal of Medicinal Chemistry June 22, 2017 Volume 60(Issue 12) pp:5029-5029
Publication Date(Web):May 24, 2017
DOI:10.1021/acs.jmedchem.7b00419
Therapies based on activation of multiple Toll-like receptors (TLRs) may offer superior therapeutic profiles than that of single TLR activation. To discover new small molecules that could activate multiple TLRs, we performed a cell-based high-throughput screening of a small-molecule library based on TLR3-mediated NF-κB activation. Subsequent structural optimization and counterscreening of other TLRs produced the first small molecule 17e (CU-CPT17e) capable of simultaneously activating TLRs 3, 8, and 9. Biochemical studies demonstrated that 17e could induce a strong immune response via the production of various cytokines in human monocytic THP-1 cells. Furthermore, 17e inhibited the proliferation of HeLa cancer cells by triggering apoptosis and arresting the cell cycle at the S phase. These results showcase potential therapeutic applications of 17e in both vaccine adjuvants and anticancer therapies based on multi-TLR activation.
Co-reporter:Kui Cheng;Dawn Béraud;Stefano G. Daniele;Hang Yin;Connor Davenport
Science Signaling 2015 Volume 8(Issue 376) pp:ra45
Publication Date(Web):12 May 2015
DOI:10.1126/scisignal.2005965
Patients with neurodegenerative disorders called synucleinopathies may benefit from drugs that inhibit inflammatory receptors on microglia in the brain.
Co-reporter:Adam Csakai ; Christina Smith ; Emily Davis ; Alexander Martinko ; Sara Coulup ;Hang Yin
Journal of Medicinal Chemistry 2014 Volume 57(Issue 12) pp:5348-5355
Publication Date(Web):May 24, 2014
DOI:10.1021/jm500409k
A series of novel, saccharin-based antagonists have been identified for the interferon signaling pathway. Through in vitro high-throughput screening with the Colorado Center for Drug Discovery (C2D2) Pilot Library, we identified hit compound 1, which was the basis for extensive structure–activity relationship studies. Our efforts produced a lead anti-inflammatory compound, tert-butyl N-(furan-2-ylmethyl)-N-{4-[(1,1,3-trioxo-2,3-dihydro-1λ6,2-benzothiazol-2-yl)methyl]benzoyl}carbamate CU-CPD103 (103), as a potent inhibitor using an established nitric oxide (NO) signaling assay. With further studies of its inhibitory mechanisms, we demonstrated that 103 carries out this inhibition through the JAK/STAT1 pathway, providing a drug-like small molecule inflammation suppressant for possible therapeutic uses.
Co-reporter:Shruti Padhee;Christina Smith;Haifan Wu;Yaqiong Li;Namitha Manoj;Qiao Qiao;Zoya Khan; Chuanhai Cao; Hang Yin; Jianfeng Cai
ChemBioChem 2014 Volume 15( Issue 5) pp:688-694
Publication Date(Web):
DOI:10.1002/cbic.201300709
Abstract
Herein we describe the development of a new class of antimicrobial and anti-inflammatory peptidomimetics: cyclic lipo-α-AApeptides. They have potent and broad-spectrum antibacterial activity against a range of clinically relevant pathogens, including both multidrug-resistant Gram-positive and Gram-negative bacteria. Fluorescence microscopy suggests that cyclic lipo-α-AApeptides kill bacteria by disrupting bacterial membranes, possibly through a mechanism similar to that of cationic host-defense peptides (HDPs). Furthermore, the cyclic lipo-α-AApeptide can mimic cationic host-defense peptides by antagonizing Toll-like receptor 4 (TLR4) signaling responses and suppressing proinflammatory cytokines such as tumor necrosis factor-α (TNF-α). Our results suggest that by mimicking HDPs, cyclic lipo-α-AApeptides could emerge as a new class of antibiotic agents that directly kill bacteria, as well as novel antiinflammatory agents that act through immunomodulation.
Co-reporter:Noah Kastelowitz ; Dr. Hang Yin
ChemBioChem 2014 Volume 15( Issue 7) pp:923-928
Publication Date(Web):
DOI:10.1002/cbic.201400043
Abstract
Exosomes and microvesicles are two classes of submicroscopic vesicle released by cells into the extracellular space. Collectively referred to as extracellular vesicles, these membrane containers facilitate important cell–cell communication by carrying a diverse array of signaling molecules, including nucleic acids, proteins, and lipids. Recently, the role of extracellular vesicle signaling in cancer progression has become a topic of significant interest. Methods to detect and target exosomes and microvesicles are needed to realize applications of extracellular vesicles as biomarkers and, perhaps, therapeutic targets. Detection of exosomes and microvesicles is a complex problem as they are both submicroscopic and of heterogeneous cellular origins. In this Minireview, we highlight the basic biology of extracellular vesicles, and address available biochemical and biophysical detection methods. Detectible characteristics described here include lipid and protein composition, and physical properties such as the vesicle membrane shape and diffusion coefficient. In particular, we propose that detection of exosome and microvesicle membrane curvature with lipid chemical probes that sense membrane shape is a distinctly promising method for identifying and targeting these vesicles.
Co-reporter:Yaqiong Li;Christina Smith;Haifan Wu;Peng Teng;Yan Shi;Shruti Padhee;Torey Jones;Anh-My Nguyen;Chuanhai Cao;Hang Yin;Jianfeng Cai
ChemBioChem 2014 Volume 15( Issue 15) pp:2275-2280
Publication Date(Web):
DOI:10.1002/cbic.201402264
Abstract
The last two decades have seen the rise of antimicrobial peptides (AMPs) to combat emerging antibiotic resistance. Herein we report the solid-phase synthesis of short lipidated α/γ-AA hybrid peptides. This family of lipo-chimeric peptidomimetics displays potent and broad-spectrum antimicrobial activity against a range of multi-drug resistant Gram-positive and Gram-negative bacteria. These lipo-α/γ-AA hybrid peptides also demonstrate high biological specificity, with no hemolytic activity towards red blood cells. Fluorescence microscopy suggests that these lipo-α/γ-AA chimeric peptides can mimic the mode of action of AMPs and kill bacterial pathogens via membrane disintegration. As the composition of these chimeric peptides is simple, therapeutic development could be economically feasible and amenable for a variety of antimicrobial applications.
Co-reporter:Xiaohui Wang, Christina Smith and Hang Yin
Chemical Society Reviews 2013 vol. 42(Issue 12) pp:4859-4866
Publication Date(Web):15 Mar 2013
DOI:10.1039/C3CS60039D
Toll-like receptors (TLRs) are type I transmembrane proteins that are key regulators of both innate and adaptive immune responses. To protect the host from viral and bacterial threats, TLRs trigger a pro-inflammatory immune response by detecting pathogen and danger associated molecular patterns. Considerable evidence has accumulated to show that the dysregulation of TLR signaling contributes to the development and progression of numerous diseases. Therefore, TLRs are emerging as important drug discovery targets. Currently, there is great interest in the development of TLR small molecule modulators for interrogating TLR signaling and treating diseases caused by TLR signaling malfunctions. In this tutorial review, we will outline methods for the discovery of TLR small molecule modulators and the up-to-date progress in this field. Small molecules targeting TLRs not only provide an opportunity to identify promising drug candidates, but also unveil knowledge regarding TLR signaling pathways.
Co-reporter:Peter N. Brown and Hang Yin
Chemical Communications 2013 vol. 49(Issue 39) pp:4415-4417
Publication Date(Web):22 Oct 2012
DOI:10.1039/C2CC36540E
Peptide nucleic acid (PNA) inhibitors of miR-221-3p (CU-PNA-221) and miR-466l-3p (CU-PNA-466) demonstrated changes in inflammatory responses. Suppression of inflammatory signalling was unexpected and further investigation led to the identification of calmodulin as a novel target of miRNA-466l-3p. These studies demonstrate that exogenous agents may suppress neuroinflammation mediated by microglial cells.
Co-reporter:Armando J. de Jesus, Noah Kastelowitz and Hang Yin
RSC Advances 2013 vol. 3(Issue 33) pp:13622-13625
Publication Date(Web):18 Jun 2013
DOI:10.1039/C3RA42332H
Highly curved bilayer lipid membranes make up the shell of many intra- and extracellular compartments, including organelles and vesicles. Using all-atom molecular dynamics simulations, we show that increasing the density of lipids in the bilayer membrane can induce the membrane to form a curved shape.
Co-reporter:Jonel P. Saludes, Leslie A. Morton, Sara K. Coulup, Zeno Fiorini, Brandan M. Cook, Lida Beninson, Edwin R. Chapman, Monika Fleshner and Hang Yin
Molecular BioSystems 2013 vol. 9(Issue 8) pp:2005-2009
Publication Date(Web):09 May 2013
DOI:10.1039/C3MB70109C
The trimer of a bradykinin derivative displayed a more than five-fold increase in binding affinity for phosphatidylserine-enriched nanovesicles as compared to its monomeric precursor. The nanovesicle selection is directly correlated with multivalency, which amplifies the electrostatic attraction. This strategy may lead to the development of novel molecular probes for detecting highly curved membrane bilayers.
Co-reporter:Shuting Zhang, Kui Cheng, Xiaohui Wang, Hang Yin
Bioorganic & Medicinal Chemistry 2012 Volume 20(Issue 20) pp:6073-6079
Publication Date(Web):15 October 2012
DOI:10.1016/j.bmc.2012.08.022
Inhibition of TLR4 signaling is an important therapeutic strategy for intervention in the etiology of several pro-inflammatory diseases. There has been intensive research in recent years aiming to explore this strategy, and identify small molecule inhibitors of the TLR4 pathway. However, the recent failure of a number of advanced drug candidates targeting TLR4 signaling (e.g., TAK242 and Eritoran) prompted us to continue the search for novel chemical scaffolds to inhibit this critical inflammatory response pathway. Here we report the identification of a group of new TLR4 signaling inhibitors through a cell-based screening. A series of arylidene malonate analogs were synthesized and assayed in murine macrophages for their inhibitory activity against LPS-induced nitric oxide (NO) production. The lead compound 1 (NCI126224) was found to suppress LPS-induced production of nuclear factor-kappaB (NF-κB), tumor necrosis factor (TNF-α), interleukin-1β (IL-1β), and nitric oxide (NO) in the nanomolar-low micromolar range. Taken together, this study demonstrates that 1 is a promising potential therapeutic candidate for various inflammatory diseases.
Co-reporter:Xiaohui Wang;Lisa C. Loram;Khara Ramos;Jacob Thomas;Andrew A. Somogyi;Kui Cheng;Armando J. de Jesus;Mark R. Hutchinson;Anireddy Reddy;Linda R. Watkins;Hang Yin
PNAS 2012 Volume 109 (Issue 16 ) pp:6325-6330
Publication Date(Web):2012-04-17
DOI:10.1073/pnas.1200130109
Opioids create a neuroinflammatory response within the CNS, compromising opioid-induced analgesia and contributing to various
unwanted actions. How this occurs is unknown but has been assumed to be via classic opioid receptors. Herein, we provide direct
evidence that morphine creates neuroinflammation via the activation of an innate immune receptor and not via classic opioid
receptors. We demonstrate that morphine binds to an accessory protein of Toll-like receptor 4 (TLR4), myeloid differentiation
protein 2 (MD-2), thereby inducing TLR4 oligomerization and triggering proinflammation. Small-molecule inhibitors, RNA interference,
and genetic knockout validate the TLR4/MD-2 complex as a feasible target for beneficially modifying morphine actions. Disrupting
TLR4/MD-2 protein–protein association potentiated morphine analgesia in vivo and abolished morphine-induced proinflammation
in vitro, the latter demonstrating that morphine-induced proinflammation only depends on TLR4, despite the presence of opioid
receptors. These results provide an exciting, nonconventional avenue to improving the clinical efficacy of opioids.
Co-reporter:Dr. Kui Cheng;Dr. Xiaohui Wang;Shuting Zhang ;Dr. Hang Yin
Angewandte Chemie 2012 Volume 124( Issue 49) pp:12412-12415
Publication Date(Web):
DOI:10.1002/ange.201204910
Co-reporter:Dr. Kui Cheng;Dr. Xiaohui Wang;Shuting Zhang ;Dr. Hang Yin
Angewandte Chemie 2012 Volume 124( Issue 49) pp:
Publication Date(Web):
DOI:10.1002/ange.201208674
Co-reporter:Dr. Kui Cheng;Dr. Xiaohui Wang;Shuting Zhang ;Dr. Hang Yin
Angewandte Chemie International Edition 2012 Volume 51( Issue 49) pp:
Publication Date(Web):
DOI:10.1002/anie.201208674
Co-reporter:Dr. Kui Cheng;Dr. Xiaohui Wang;Shuting Zhang ;Dr. Hang Yin
Angewandte Chemie International Edition 2012 Volume 51( Issue 49) pp:12246-12249
Publication Date(Web):
DOI:10.1002/anie.201204910
Co-reporter:Jing Li, Xiaohui Wang, Fengchun Zhang, Hang Yin
Pharmacology & Therapeutics (June 2013) Volume 138(Issue 3) pp:441-451
Publication Date(Web):1 June 2013
DOI:10.1016/j.pharmthera.2013.03.003
Autoimmune connective tissue diseases (ACTDs) are a family of consistent systemic autoimmune inflammatory disorders, including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc) and Sjögren's syndrome (SS). IL-1R-like receptors (TLRs) are located on various cellular membranes and sense exogenous and endogenous danger-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs), playing a critical role in innate immune responses. During the past decade, the investigation of TLRs in inflammatory autoimmune diseases has been fruitful. In this report, we review the significant biochemical, physiological and pathological studies of the key functions of TLRs in ACTDs. Several proteins in the TLR signaling pathways (e.g., IKK-2 and MyD88) have been identified as potential therapeutic targets for the treatment of ACTDs. Antibodies, oligodeoxyribonucleotides (ODNs) and small molecular inhibitors (SMIs) have been tested to modulate TLR signaling. Some drug-like SMIs of TLR signaling, such as RDP58, ST2825, ML120B and PHA-408, have demonstrated remarkable potential, with promising safety and efficacy profiles, which should warrant further clinical investigation. Nonetheless, one should bear in mind that all TLRs exert both protective and pathogenic functions; the function of TLR4 in inflammatory bowel disease represents such an example. Therefore, an important aspect of TLR modulator development involves the identification of a balance between the suppression of disease-inducing inflammation, while retaining the beneficiary host immune response.
Co-reporter:Christina Smith, Xiaohui Wang, Hang Yin
Trends in Immunology (February 2015) Volume 36(Issue 2) pp:59-61
Publication Date(Web):1 February 2015
DOI:10.1016/j.it.2014.12.007
Caspases are cellular executors, initiating cell death. In a recent study, Shi et al. report that caspases 4/5/11 are cytosolic LPS receptors, becoming activated through oligomerization upon interaction with LPS. These findings shed new light on the mechanisms underlying caspase-mediated pyroptosis, and have implications for the development of effective drugs to treat sepsis.
Co-reporter:Armando J. de Jesus, Ormacinda R. White, Aaron D. Flynn, Hang Yin
Biophysical Journal (10 May 2016) Volume 110(Issue 9) pp:
Publication Date(Web):10 May 2016
DOI:10.1016/j.bpj.2016.04.007
It is increasingly recognized that membrane curvature plays an important role in various cellular activities such as signaling and trafficking, as well as key issues involving health and disease development. Thus, curvature-sensing peptides are essential to the study and detection of highly curved bilayer structures. The effector domain of myristoylated alanine-rich C-kinase substrate (MARCKS-ED) has been demonstrated to have curvature-sensing ability. Research of the MARCKS-ED has further revealed that its Lys and Phe residues play an essential role in how MARCKS-ED detects and binds to curved bilayers. MARCKS-ED has the added property of being a lower-molecular-weight curvature sensor, which offers advantages in production. With that in mind, this work investigates peptide-sequence-related factors that influence curvature sensing and explores whether peptide fragments of even shorter length can function as curvature sensors. Using both experimental and computational methods, we studied the curvature-sensing capabilities of seven fragments of MARCKS-ED. Two of the longer fragments were designed from approximately the two halves of the full-length peptide whereas the five shorter fragments were taken from the central stretch of MARCKS-ED. Fully atomistic molecular dynamics simulations show that the fragments that remain bound to the bilayer exhibit interactions with the bilayer similar to that of the full-length MARCKS-ED peptide. Fluorescence enhancement and anisotropy assays, meanwhile, reveal that five of the MARCKS fragments possess the ability to sense membrane curvature. Based on the sequences of the curvature-sensing fragments, it appears that the ability to sense curvature involves a balance between the numbers of positively charged residues and hydrophobic anchoring residues. Together, these findings help crystallize our understanding of the molecular mechanisms underpinning the curvature-sensing behaviors of peptides, which will prove useful in the design of future curvature sensors.
Co-reporter:Peter N. Brown and Hang Yin
Chemical Communications 2013 - vol. 49(Issue 39) pp:NaN4417-4417
Publication Date(Web):2012/10/22
DOI:10.1039/C2CC36540E
Peptide nucleic acid (PNA) inhibitors of miR-221-3p (CU-PNA-221) and miR-466l-3p (CU-PNA-466) demonstrated changes in inflammatory responses. Suppression of inflammatory signalling was unexpected and further investigation led to the identification of calmodulin as a novel target of miRNA-466l-3p. These studies demonstrate that exogenous agents may suppress neuroinflammation mediated by microglial cells.
Co-reporter:Xiaohui Wang, Christina Smith and Hang Yin
Chemical Society Reviews 2013 - vol. 42(Issue 12) pp:NaN4866-4866
Publication Date(Web):2013/03/15
DOI:10.1039/C3CS60039D
Toll-like receptors (TLRs) are type I transmembrane proteins that are key regulators of both innate and adaptive immune responses. To protect the host from viral and bacterial threats, TLRs trigger a pro-inflammatory immune response by detecting pathogen and danger associated molecular patterns. Considerable evidence has accumulated to show that the dysregulation of TLR signaling contributes to the development and progression of numerous diseases. Therefore, TLRs are emerging as important drug discovery targets. Currently, there is great interest in the development of TLR small molecule modulators for interrogating TLR signaling and treating diseases caused by TLR signaling malfunctions. In this tutorial review, we will outline methods for the discovery of TLR small molecule modulators and the up-to-date progress in this field. Small molecules targeting TLRs not only provide an opportunity to identify promising drug candidates, but also unveil knowledge regarding TLR signaling pathways.